Thus, although both BM-MSCs and AT-MSCs were effective in attenuating neuronal loss and changes in nNOS and ChAT immunoreactivity, AT-MSCs were less efficacious compared to BM-MSCs in treating neuropathy. This evidence concerns the gene NOS1 and neuropathy.